Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML
May 31, 2024 08:00 ET
|
Novartis Pharma AG
Phase III ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results; Scemblix® (asciminib) demonstrated superior MMR rates at week 48 vs....
PRESS RELEASE: BIGBEN WEEK 2024: NACON PRESENTS AN AMBITOUS LINE-UP AND ANNOUNCES A NEW DEPARTMENT DEDICATED TO RACING
May 30, 2024 02:00 ET
|
NACON
BIGBEN WEEK 2024 NACON PRESENTS AN AMBITOUS LINE-UP AND ANNOUNCES A NEW DEPARTMENT DEDICATED TO RACING During the annual Bigben Group event, NACON has announced the creation of a department...
COMMUNIQUE DE PRESSE: BIGBEN WEEK 2024: NACON PRÉSENTE UN LINE UP AMBITIEUX ET ANNONCE UN NOUVEAU PÔLE DÉDIÉ AU RACING
May 30, 2024 02:00 ET
|
NACON
- BIGBEN WEEK 2024 – NACON PRÉSENTE UN LINE UP AMBITIEUX ET ANNONCE UN NOUVEAU PÔLE DÉDIÉ AU RACING Lors de l’événement annuel du Groupe Bigben, NACON annonce la création d’un département dédié...
Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress
May 28, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
– Results from Preclinical Model of Hyperphosphatemia Demonstrate the Relative Potency of OLC Compared to Tenapanor – – Oral UNI-494 Shows Promise in a Preclinical Model as a Potential Candidate...
MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions
May 28, 2024 06:00 ET
|
MediciNova, Inc.
LA JOLLA, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange...
Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences
May 23, 2024 08:30 ET
|
Inozyme Pharma Inc.
BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for...
First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
May 22, 2024 08:00 ET
|
Esperion Therapeutics, Inc.
– NILEMDO (bempedoic acid), a First-In-Class, Oral Treatment and NUSTENDI (bempedoic Acid / Ezetimibe Fixed-Dose Combination) Receive Label Update Approval from The European Commission as Treatments...
Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
May 20, 2024 06:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 20, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) and Otsuka Pharmaceutical Co., Ltd (Otsuka) announced today that the primary endpoint was achieved in the Phase 3 trial in...
Osten & Victor Alberta Tennis Centre launches Everyone Can Play Program to create inclusivity promoting tennis as a sport for everyone
May 15, 2024 14:15 ET
|
Osten & Victor Alberta Tennis Centre
CALGARY, Alberta, May 15, 2024 (GLOBE NEWSWIRE) -- Today, The Osten & Victor Alberta Tennis Centre (The ATC) held a press conference to announce the launch of its new Everyone Can Play program,...
Sportradar Reports First Quarter 2024 Financial and Operating Results
May 15, 2024 07:00 ET
|
Sportradar AG
Achieved Record Revenue of €266 Million, Up 28% and Grew Adjusted EBITDA 29% Raising 2024 Outlook for Revenue and Adjusted EBITDA Commencing Purchases Under Previously Announced Share Repurchase...